Rahul Koul

1 month ago | biovoicenews.com | Rahul Koul

New Delhi: In 2023, Tuberculosis (TB) reclaimed its position as the leading cause of death from a single infectious agent, surpassing COVID-19, with 1.25 million fatalities worldwide. India, contributing over a quarter of global TB cases, remains a hotspot. Meanwhile, the advancements in treatment, including discovery of the novel drug Bedaquiline, have significantly improved drug-resistant TB management as well as overall survival rates in these patients.

2 months ago | biovoicenews.com | Rahul Koul

In an exclusive interview, Dr VJA Gutla Harshavardhan, Director General, Indian Vaccine Manufacturers Association (IVMA) shares his insights on the importance of vaccines, evolution of vaccine industry in India and role played by IVMA on the occasion of national immunization day 2025. Dr Harshavardhan, for our readers who may not fully understand the science behind vaccines, could you explain what immunization with vaccines actually is and how it works?

2 months ago | biovoicenews.com | Rahul Koul

In an exclusive interview, Dr VJA Gutla Harshavardhan, Director General, Indian Vaccine Manufacturers Association (IVMA) shares his insights on the importance of immunization, vaccine hesitancy and role played by IVMA. Dr Harshavardhan, for our readers who may not fully understand the science behind vaccines, could you explain what immunization with vaccines actually is and how it works? To understand immunization, we must think of it as a training camp for our body’s defence forces.

2 months ago | biovoicenews.com | Rahul Koul

Dr Abdelaziz Toumi, CEO – Lupin Manufacturing Solutions is a passionate leader with a blend of scientific and commercial skills. He brings over 20 years of experience in the biotech, pharma and CDMO sectors, spanning Europe, North America, and Asia. Abdel heads Lupin’s API CDMO business, a division that provides custom development and manufacturing of active pharmaceutical ingredients for clients worldwide.

2 months ago | biovoicenews.com | Rahul Koul

Over the years, India has made noteworthy strides in tackling Tuberculosis (TB), signaling a commitment to achieving its ambitious goal of eliminating the disease by 2025, five years ahead of the global Sustainable Development Goal (SDG) target. The rate of TB decline in India from 2015 to 2024 is 17.7% which is double that of the global average of 8.3%. The deaths due to TB have reduced significantly in India by 21.4% in the last 10 years.